Eczema Herpeticum: Clinical and Pathophysiological Aspects.
Damour. Alexia A; Garcia. Magali M; Seneschal. Julien J; Lévêque. Nicolas N; Bodet. Charles C
Key Findings
- s antimicrobial defense.",
- ,
Practical Outcomes
- For biohackers, the main takeaway is that supporting skin barrier health and possibly boosting LL‑37 (e.g., through vitamin D, topical agents, or microbiome-friendly practices) could reduce viral flare‑ups in eczema. However, the abstract does not provide specific dosing or proven interventions, so any protocol would be experimental and should be approached cautiously.
Summary
The review explains why people with eczema (atopic dermatitis) are more likely to get a serious herpes skin infection called eczema herpeticum. One key reason is that their skin makes less of the natural antimicrobial peptide LL‑37, which normally helps fight microbes and viruses. Other factors include skin barrier problems, immune signaling changes, and bacterial overgrowth.
Abstract
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the world. AD is a complex pathology mainly characterized by an impaired skin barrier, immune response dysfunction, and unbalanced skin microbiota. Moreover, AD patients exhibit an increased risk of developing bacterial and viral infections. One of the most current, and potentially life-threatening, viral infection is caused by herpes simplex virus (HSV), which occurs in about 3% of AD patients under the name of eczema herpeticum (EH). Following a first part dedicated to the clinical features, virological diagnosis, and current treatments of EH, this review will focus on the description of the pathophysiology and, more particularly, the presently known predisposing factors to herpetic complications in AD patients. These factors include those related to impairment of the skin barrier such as deficit in filaggrin and anomalies in tight and adherens junctions. In addition, low production of the antimicrobial peptides cathelicidin LL-37 and human β-defensins; overexpression of cytokines such as interleukin (IL)-4, IL-13, IL-25, IL-33, and thymic stromal lymphopoietin (TSLP); or downregulation of type I to III interferons as well as defect in functions of immune cells such as dendritic, natural killer, and regulatory T cells have been involved. Otherwise, genetic polymorphisms and AD topical calcineurin inhibitor treatments have been associated with an increased risk of EH. Finally, dysbiosis of skin microbiota characterized in AD patients by Staphylococcus aureus colonization and toxin secretion, such as α-toxin, has been described as promoting HSV replication and could therefore contribute to EH.
Study Information
pubmed
2020
2019-12-13T00:00:00.000Z
10.1007/s12016-019-08768-3
67
137